Lupin soars on receiving USFDA`s approval for Rivaroxaban for Oral Suspension
Lupin is currently trading at Rs. 1959.85, up by 49.70 points or 2.60% from its previous closing of Rs. 1910.15 on the BSE.
The scrip opened at Rs. 1929.95 and has touched a high and low of Rs. 1975.40 and Rs. 1926.10 respectively. So far 1926 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2403.45 on 02-Jan-2025 and a 52 week low of Rs. 1774.00 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 2034.95 and Rs. 1901.45 respectively. The current market cap of the company is Rs. 87247.60 crore.
The promoters holding in the company stood at 46.90%, while Institutions and Non-Institutions held 46.81% and 6.28% respectively.
Lupin has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Rivaroxaban for Oral Suspension, 1 mg/mL, which is bioequivalent to Xarelto for Oral Suspension, 1 mg/mL of Janssen Pharmaceuticals, Inc. The product will be manufactured at the company's Chhatrapati Sambhajinagar facility in India.
Rivaroxaban for Oral Suspension is indicated for treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years after at least 5 days of initial parenteral anticoagulant treatment; and for treatment of thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure. Rivaroxaban for Oral Suspension, 1 mg/mL (RLD Xarelto) had estimated annual sales of $11 million in the U.S. (IQVIA MAT July 2025).
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
